ASCO 2012
American Society of Clinical Oncology Annual Meeting
Interviews and expert commentary from ASCO 2012 — study authors and key opinion leaders discuss the findings and their clinical implications.
Official website ↗
ASCO 2012 ANNUAL MEETING: Outgoing ASCO President Michael Link Comments On Key New Clinical Research Findings
CHICAGO—The outgoing president of ASCO, Dr Michael Link from Stanford University School of Medicine in California, answers questions from Peter Goodwin about the progress achieved in cancer clinical s
ASCO 2012 ANNUAL MEETING: Targeted Drug Afatinib Delays Progression of Advanced Lung Cancers, Particularly Those With Specific Genetic Mutations
CHICAGO—Findings from a Phase III trial show that initial single-agent therapy with a new oral drug called afatinib prolongs progression- free survival in patients with advanced lung adenocarcinomas t
ASCO 2012 ANNUAL MEETING: Resolving Long Debate, Study Finds Intermittent Hormonal Therapy Less Effective than Continuous Therapy in Certain Men With Advanced Prostate Cancer
CHICAGO—At the Plenary Session of ASCO Maha Hussain MD, FACP of the University of Michigan in Ann Arbor presented results from a long-term, multicenter Phase III international clinical trial comparing
Childhood Cancer Treatment: Model For Adult Therapy — ASCO President
STOCKHOLM—The first specialist in pediatric oncology ever to hold office as President of the American Society of Clinical Oncology, Dr Michael Link — Professor of Pediatrics at Stanford University Sch